247 related articles for article (PubMed ID: 34132492)
1. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
Verma S; Leiter LA; Zinman B; Sharma A; Mattheus M; Fitchett D; George J; Ofstad AP; Kosiborod MN; Wanner C; Inzucchi SE
ESC Heart Fail; 2021 Aug; 8(4):2603-2607. PubMed ID: 34132492
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
4. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
[TBL] [Abstract][Full Text] [Related]
5. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
[TBL] [Abstract][Full Text] [Related]
7. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Fitchett D; Inzucchi SE; Wanner C; Mattheus M; George JT; Vedin O; Zinman B; Johansen OE
Eur Heart J; 2020 Jan; 41(2):209-217. PubMed ID: 31504427
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
9. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
Fitchett D; Inzucchi SE; Zinman B; Wanner C; Schumacher M; Schmoor C; Ohneberg K; Ofstad AP; Salsali A; George JT; Hantel S; Bluhmki E; Lachin JM; Zannad F
ESC Heart Fail; 2021 Dec; 8(6):4517-4527. PubMed ID: 34605192
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
[TBL] [Abstract][Full Text] [Related]
11. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE; Zinman B; Fitchett D; Wanner C; Ferrannini E; Schumacher M; Schmoor C; Ohneberg K; Johansen OE; George JT; Hantel S; Bluhmki E; Lachin JM
Diabetes Care; 2018 Feb; 41(2):356-363. PubMed ID: 29203583
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
Neeland IJ; Eliasson B; Kasai T; Marx N; Zinman B; Inzucchi SE; Wanner C; Zwiener I; Wojeck BS; Yaggi HK; Johansen OE;
Diabetes Care; 2020 Dec; 43(12):3007-3015. PubMed ID: 33004464
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Zinman B; Inzucchi SE; Lachin JM; Wanner C; Ferrari R; Fitchett D; Bluhmki E; Hantel S; Kempthorne-Rawson J; Newman J; Johansen OE; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2014 Jun; 13():102. PubMed ID: 24943000
[TBL] [Abstract][Full Text] [Related]
16. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME
Kaku K; Lee J; Mattheus M; Kaspers S; George J; Woerle HJ;
Circ J; 2017 Jan; 81(2):227-234. PubMed ID: 28025462
[TBL] [Abstract][Full Text] [Related]
18. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Coleman RL; Gray AM; Broedl Md UC; Fitchett D; George JT; Woerle HJ; Zinman B; Holman RR
Diabetes Obes Metab; 2020 Jul; 22(7):1151-1156. PubMed ID: 32115840
[TBL] [Abstract][Full Text] [Related]
19. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
[TBL] [Abstract][Full Text] [Related]
20. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME.
Pellicori P; Ofstad AP; Fitchett D; Zeller C; Wanner C; George J; Zinman B; Brueckmann M; Lindenfeld J
ESC Heart Fail; 2020 Dec; 7(6):3401-3407. PubMed ID: 32915523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]